contd a1

hydroxy, or two adjacent R_1 groups together with the carbon atoms to which they are attached forming a fused benzene ring.

6. Compounds according to claim 1, wherein R_1 represents methoxy, fluoro, chloro, hydroxy, or two adjacent R_1 groups together with the carbon atoms to which they are attached forming a fused benzene ring.

7. Compounds according to claim 1, wherein R_2 is H or an alkyl group containing 1 to 3 carbon atoms.

8. Compounds according to claim 1, wherein R_3 and R_4, which are the same or different, are H or methyl.

9. Compounds according to claim 1, wherein T is pyridyl, pyrimidinyl, pyrazinyl, phenyl, benzofuryl, 1,4-benzodioxanyl or quinazolinyl all optionally substituted by methoxy, trifluoromethyl, or halo.

10. Compounds according to claim 1, wherein T is 2-pyridyl, 2-pyrimidinyl, 2-pyrazinyl, phenyl, 2,3-dihydrobenzo [b] furan-7 yl, 1,4-benzodioxan-5-yl or 4-quinazolinyl all optionally substituted by methoxy, trifluoromethyl, or halo.

11. Compounds according to claim 1, wherein R_5 is H or methyl.

12. Compounds according to claim 1, which are:

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (pyrazin-2-yl) piperid-4-yl] methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4-yl] methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (3-chloropyrid-2-yl) piperid-4-yl] methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (quinazolin-4-yl) piperid-4-yl] methylamine;

contd. A1

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (pyrid-2-yl) piperid-4-yl] methylamine; N- (8-Methoxy-1, 4-benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4yl] methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-N'- [3- (trifluoromethyl)-2-pyridyl] ethanediamine;

N- (8-Methoxy-1, 2, 3, 4-tetrahydronaphth-2-ylmethyl)-1- [1-pyrimidin-2-yl) piperid-4- yl] methylamine;

7- {B-[1-(Pyrimidin-2-yl) piperid-4-ylmethyl] aminomethyl}-5,{B-[1-(Pyrimidin-2-yl) piperid-4-ylmethyl] aminomethyl}-5, 6, 7, 8-tetrahydronaphth-1ol;

N- (5-Methoxy-3, 4-dihydro-2H-1-benzopyran-3-ylmethyl)-1- [1-(pyrimidin-2-yl) piperid 4-yl] methylamine; N- (1, 4-Benzodioxan-2-ylmethyl)-1-(1-phenylpiperid-4-yl) methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (1, 4-benzodioxan-5-yl) piperid-4yl] methylamine;

1- [1- (1, 4-Benzodioxan-2-ylmethyl) piperid-4-yl]-N- (2-methoxyphenyl) methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (4-methoxyphenyl) piperid-4-yl] methylamine;

N- (8-Methoxy-1, 4-benzodioxan-2-ylmethyl)-N- (2-methoxyphenyl)-1, 3-propanediamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (3-methoxyphenyl) piperid-4-yl] methylamine;

N- (6, 7-Dichloro-1, 4-benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4yl] methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (2-chlorophenyl) piperid-4-yl] methylamine;

N- (5-Fluoro-1, 4-benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4yl] methylamine;

N- (8-Fluoro-1, 4-benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4yl] methylamine;

contd. a1

1- [1- (2-methoxyphenyl) piperid-4-yl]-N- (naphtho [1, 2-b] dioxan-2ylmethyl) methylamine; 1- [1- (2, 3-Dihydrobenzo [b] furan-7-yl) piperid-4-yl]-N- (8-methoxy-1, 4-benzodioxan-2- ylmethyl) methylamine;

N- (6-Chloro-1, 4-benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4yl] methylamine;

N- (7-Chloro-1, 4-benzodioxan-2-ylmethyl)-1- (1- (2-methoxyphenyl) piperid-4yl] methylamine;

N- (8-hydroxy-1, 4-benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4yl] methylamine; [and] or pharmaceutically acceptable salts thereof in the form of individual enantiomers, racemates, or other mixtures of enantiomers.

13. Compounds according to claim 12, which are:

(S)- (-)-N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4yl] methylamine;

(R)- (+)-N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4yl] methylamine;

(-)-N- (1, 4-Benzodioxan-2-ylmethyl)-l- [l- (pyrid-2-yl) piperid-4-yl] methylamine dihydrochloride; or

(+)-N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (pyrid-2-yl) piperid-4-yl] methylamine dihydrochloride.

14. A method for reducing cravings to food or an addictive substance, comprising:

administering a therapeutically effective amount of a compound of formula I



contd
a1

or pharmaceutically acceptable salts thereof in the form of individual enantiomers, racemates, or other mixtures of enantiomers, in which:

A is-0-;

Bis-0-;

g is 0 or 1;

R_1 represents halo, an alkyl group containing 1 to 3 carbon atoms, an alkoxy group containing 1 to 3 carbon atoms, or hydroxy;

R_2, R_3 and R_4 are each H;

U is methylene;

Q is a group of formula IIa



or IIc



in which V is methylene or ethylene; X is an alkylene chain containing 0 to 2 carbon atoms and X'is an alkylene chain containing 1 to 4 carbon atoms provided that the total number of carbon atoms in X and X' amounts to 3 or 4; and R_5 is H; and
T is pyridyl, pyrazinyl, phenyl, benzo [b] furanyl, 1,4-benzodioxanyl, or quinazolinyl all optionally substituted by methoxy, trifluoromethyl, or halo.

15. A method according to claim 14 wherein R_1 represents methoxy, fluoro, chloro or hydroxy.

contd.
a1

16. A method according to claim 14, wherein T is 2pyridyl, 2-pyrazinyl, phenyl, 2, 3-dihydrobenzo [b] furan-7-yl, 1, 4-benzodioxan-5-yl or 4quinazolinyl all optionally substituted by methoxy, trifluoromethyl, or halo.

17. A method according to claim 14, wherein the compounds of formula 1 are selected from:

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (pyrazin-2-yl) piperid-4-yl] methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4-yl] methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (3-chloropyrid-2-yl) piperid-4-yl] methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (quinazolin-4-yl) piperid-4-yl] methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (pyrid-2-yl) piperid-4-yl] methylamine;

N- (8-Methoxy-1, 4-benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4yl] methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- (1-phenylpiperid-4-yl) methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (1, 4-benzodioxan-5-yl) piperid-4yl] methylamine;

1- [1- (1, 4-Benzodioxan-2-ylmethyl) piperid-4-yl]-N- (2-methoxyphenyl) methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (4-methoxyphenyl) piperid-4-yl] methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (3-methoxyphenyl) piperid-4-yl] methylamine;

N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (2-chlorophenyl) piperid-4-yl] methylamine;

N- (5-Fluoro-1, 4-benzodioxan-2-ylmethyl)-l- [l- (2-methoxyphenyl) piperid-4yl] methylamine;

contd.
a1

N- (8-Fluoro-1, 4-benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4yl] methylamine;

1- [1- (2, 3-Dihydrobenzo [b] furan-7-yl) piperid-4-yl]-N- (8-methoxy-1, 4-benzodioxan-2- ylmethyl) methylamine;

N- (6-Chloro-1, 4-benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4yl] methylamine;

N- (7-Chloro-1, 4-benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4yl] methylamine;

N- (8-hydroxy-1, 4-benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4yl] methylamine; and

pharmaceutically acceptable salts thereof in the form of individual enantiomers, racemates, or other mixtures of enantiomers.

18. A method according to claim 14 wherein the compounds of formula 1 are selected from:

(S)- (-)-N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4- yl] methylamine;

(R)- (+)-N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4yl] methylamine;

(-)-N- (1, 4-Benzodioxan-2-ylmethyl)-1- [1- (pyrid-2-yl) piperid-4-yl] methylamine dihydrochloride; and

(+)-N-(1, 4-Benzodioxan-2-ylmethyl)-1-[1-(pyrid-2-yl) piperid-4-yl] methylamine dihydrochloride.

19. A method according to claim 14 wherein the compounds of formula 1 are selected from:

N- (7-Chloro-1, 4-benzodioxan-2-ylmethyl)-1- [1- (2-methoxyphenyl) piperid-4yl]methylamine; and

pharmaceutically acceptable salts thereof in the form of individual enantiomers, racemates, or other mixtures of enantiomers.

contd. a1

20. A method for reducing cravings to food or an addictive substance, comprising:

administering a therapeutically effective amount of a compound of formula 1, together with a pharmaceutically acceptable diluent or carrier in reducing cravings to food or an addictive substance.

Remarks

Claims 2-20 have been amended and claim 23 has been canceled. Support for "administering a therapeutically effective amount" can be found on page 7, line 25 and pages 8-12 of the above application.

Conclusion

All claims presently in the application are believed to be allowable over the art of record and early notice to that effect is respectfully solicited. Please charge any additional fee required for the timely consideration of this application to Deposit Account No. 19-4972.

Respectfully submitted,

Harriet Strimpel

Harriet M. Strimpel, D.Phil.
Registration No. 37,008
Attorney for Applicant
Bromberg & Sunstein
125 Summer Street
Boston, MA 02110
617/443 9292

January 4, 2002
02544/00001 186076.1